https://allsci.com/news/clinical-trials/neoantigen-therapy-melanoma-merck-and-modernas/ AllScien 2026-08-19T12:08:14.955167Z Merck, Moderna neoantigen therapy delivers landmark Phase III melanoma win https://allsci.com/news/research/senolytic-drug-mycobacterial-infection-senescent/ AllScien 2026-08-19T12:04:38.302544Z University of Milan team turns senolytic drug against hard-to-treat mycobacterial infection https://allsci.com/news/grants/type-1-diabetes-biomarkers-battelle-pacific/ AllScien 2026-08-19T08:51:11.081574Z NIH funds new blood biomarkers to track islet dysfunction in type 1 diabetes https://allsci.com/news/grants/oral-influenza-antiviral-stanford-secures-127m/ AllScien 2026-08-19T08:45:28.426804Z Stanford moving novel oral influenza antiviral toward IND with NIAID backing https://allsci.com/news/licensing-and-partnerships/eli-lilly-alzheimers-gsm-completes-usd-10-million/ AllScien 2026-08-19T08:41:59.751117Z Lilly completes USD 10m payment for preclinical Alzheimer's GSM from AlzeCure https://allsci.com/news/regulatory/pelareorep-colorectal-cancer-fda-aligns-with/ AllScien 2026-08-19T08:38:40.670386Z Oncolytics gains FDA alignment on pivotal path for pelareorep in colorectal cancer https://allsci.com/news/regulatory/parg-inhibitor-breast-cancer-858-therapeutics/ AllScien 2026-08-19T08:34:45.703514Z 858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer https://allsci.com/news/policy/fda-generative-ai-medical-devices-seeks-public/ AllScien 2026-08-19T08:32:33.861243Z FDA seeks input on regulatory framework for generative AI-enabled medical devices https://allsci.com/news/funding/avexitide-funding-phase-iii-amylyx-raises-usd/ AllScien 2026-08-19T08:28:49.525119Z Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win https://allsci.com/news/licensing-and-partnerships/gsk-dengue-antibody-license-secures-exclusive/ AllScien 2026-08-19T08:13:42.286884Z GSK secures preclinical dengue antibody from Chugai https://allsci.com/news/development/biomarin-alesta-acquisition-hypophosphatasia/ AllScien 2026-08-18T17:19:00.312056Z BioMarin pays USD 275m upfront for early-stage oral HPP bet ALE1 https://allsci.com/news/grants/alzheimers-prevention-down-syndrome-brigham-and/ AllScien 2026-08-18T17:13:40.927362Z Brigham wins NIA funding to test lamivudine against retrotransposons in Down syndrome Alzheimer's https://allsci.com/news/research/virtual-cell-simulation-genbio-ai-releases-aido/ AllScien 2026-08-18T16:52:56.695334Z GenBio AI unveils multiscale virtual cell model spanning DNA to phenotype https://allsci.com/news/clinical-trials/exercise-mimicking-obesity-pill-envedas-shows/ AllScien 2026-08-18T15:59:33.353125Z Enveda clears Phase I with exercise-inspired pill targeting post-GLP-1 weight regain https://allsci.com/news/funding/neurothera-labs-funding-scisparc-funds-spinoff/ AllScien 2026-08-18T15:55:11.768406Z SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round https://allsci.com/news/venture-financing/abcuro-series-d-funding-raises-usd-66m-to-advance/ AllScien 2026-08-18T15:53:37.627889Z Abcuro raises USD 66m to retest ulviprubart after Phase II/III IBM miss https://allsci.com/news/grants/aml-treatment-resistance-research-dana-farber/ AllScien 2026-08-18T15:47:09.405058Z Dana-Farber wins NCI leukemia SPORE to tackle resistance across emerging AML drug classes https://allsci.com/news/regulatory/fda-fast-track-endometrial-cancer-grants/ AllScien 2026-08-18T14:27:26.355309Z Faeth's PIKTOR combo gets FDA fast track for biomarker-selected endometrial cancer https://allsci.com/news/clinical-trials/novo-nordisk-obesity-trial-registers-phase-with/ AllScien 2026-08-18T14:20:56.033813Z Novo Nordisk takes mystery obesity drug into FIH trial against semaglutide https://allsci.com/news/research/bacillus-cereus-immunotherapy-hepatocellular-carcinoma/ AllScien 2026-08-18T13:55:00.020362Z Nanjing Medical University researchers link bacterial enzyme to improved liver cancer immunotherapy https://allsci.com/news/pharma/dersimelagon-acquisition-leo-pharma-acquires-for/ AllScien 2026-08-18T12:26:24.981307Z LEO Pharma picks up dersimelagon for USD 435m to challenge Scenesse in rare photodermatoses https://allsci.com/news/ipo-public-listing/ingenia-therapeutics-kosdaq-listing-lists-on-to/ AllScien 2026-08-18T12:20:27.160834Z Ingenia Therapeutics lists on KOSDAQ to fund vascular antibody pipeline https://allsci.com/news/clinical-trials/avexitide-hypoglycemia-phase-iii-amylyxs-cuts/ AllScien 2026-08-18T12:16:46.921291Z Amylyx's avexitide cuts hypoglycemic events by 55% in Phase III post-bariatric trial https://allsci.com/news/first-in-human-trials/atx-898-clinical-trial-antares-launches/ AllScien 2026-08-18T10:48:34.407075Z Antares launches FIH trial of ATX-898 with CDK4/6 breast cancer combos https://allsci.com/news/first-in-human-trials/mek-inhibitor-wet-amd-trial-filamon-launches/ AllScien 2026-08-18T10:24:46.702003Z Filamon launches first-in-human trial of topical MEK inhibitor in wet AMD https://allsci.com/news/licensing-and-partnerships/omniab-eli-lilly-deal-secures-usd-370m-milestone/ AllScien 2026-08-17T16:25:49.399249Z Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m https://allsci.com/news/ipo-public-listing/slate-medicines-ipo-merger-goes-public-via/ AllScien 2026-08-17T16:19:48.386964Z Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field https://allsci.com/news/clinical-trials/duravyu-wet-amd-trial-eyepoints-misses-primary/ AllScien 2026-08-17T16:14:48.558007Z EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path https://allsci.com/news/preclinical/namodenoson-pancreatic-cancer-can-fites-boosts/ AllScien 2026-08-17T16:11:02.368633Z Can-Fite's namodenoson boosts gemcitabine potency in pancreatic cancer preclinical models https://allsci.com/news/clinical-trials/bispecific-car-t-lymphoma-abelzeta-reclaims/ AllScien 2026-08-17T15:59:50.137252Z J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T https://allsci.com/news/licensing-and-partnerships/immune-cell-therapy-partnership-biocytics-and/ AllScien 2026-08-17T15:50:28.263486Z BioCytics and LIDE Biotech partner to validate immune cell therapies in patient-derived tumor models https://allsci.com/news/venture-financing/glutaminase-inhibitor-schizophrenia-leal/ AllScien 2026-08-17T15:22:10.812704Z Leal Therapeutics raises USD 30m to advance glutaminase inhibitor in schizophrenia https://allsci.com/news/clinical-trials/volrustomig-trial-discontinuation-astrazeneca/ AllScien 2026-08-17T15:13:53.827710Z AstraZeneca drops Phase III volrustomig trial after pembrolizumab challenge fails https://allsci.com/news/research/friedreichs-ataxia-treatment-myeloid-cell/ AllScien 2026-08-17T14:56:57.831598Z Myeloid cell transplantation rescues Friedreich's ataxia through mitochondrial transfer in mice https://allsci.com/news/preclinical/hdac-inhibition-cancer-university-of-pittsburgh/ AllScien 2026-08-17T14:26:31.703840Z Pitt, Magee-Womens team turns cancer dormancy into a druggable vulnerability https://allsci.com/news/research/polyamines-ferroptosis-whitehead-institute/ AllScien 2026-08-17T13:53:34.219382Z Cell study uncovers polyamines as natural ferroptosis defense https://allsci.com/news/licensing-and-partnerships/oral-peptide-therapeutics-ai-aizen-applies/ AllScien 2026-08-17T12:59:34.375538Z Aizen lands multi-program oral peptide deal worth up to USD 100m per target https://allsci.com/news/funding/silence-therapeutics-divesiran-funding-raises-usd-1/ AllScien 2026-08-17T12:44:54.892958Z Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial https://allsci.com/news/licensing-and-partnerships/sandoz-henlius-biosimilars-partnership-expands-to/ AllScien 2026-08-17T12:42:20.516498Z Sandoz expands Henlius partnership to cover up to 10 biosimilars for USD 322m